ArticleBio-protocol2026
Tandem RNA and Protein Extraction: A Platform for Maximizing the Use of Limited Ex Vivo Tissue Samples.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human tissue samples represent the gold standard for obtaining clinically relevant and translatable insight into disease processes that in vitro systems cannot fully reproduce. However, patient-derived samples are often limited in size and availability, limiting the number of downstream assays that can be performed. To maximize the use of invaluable human samples, we present a protocol for the tandem extraction of high-quality RNA and protein from the same tissue section. This method has been optimized for 15-30 mg tissue sections, enabling more experimental conditions and technical replicates, while minimizing intrasample variability associated with heterogeneous tissues. This protocol also avoids potentially hazardous solvents present in phenol-chloroform-based methods such as TRIzol, providing a safer and more accessible workflow without compromising biomolecule integrity. This protocol was developed and validated using atherosclerotic plaque tissue from carotid endarterectomy, a very challenging tissue type to work with due to extensive calcification, necrosis, and limited surgical availability. We have also validated this method using mouse aortic tissue and cultured THP-1 cells, demonstrating its versatility across sample input types. As this protocol relies on standard column-based RNA extraction kits and commonly available reagents for protein precipitation and extraction, this methodology is widely accessible and easy to implement as a standard, streamlined workflow. Key features • Advances ex vivo models of human disease (e.g., atherosclerosis) by maximizing the use of patient-derived tissue samples. • Minimizes patient variability by generating directly comparable RNA and protein readouts. • Minimizes the number of patient samples required and maximizes the output from each sample. • Stabilizes RNA integrity from tissue without impacting the quality of proteins derived from the same sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.